patients with end-stage renal disease on chronic peritoneal dialysis and with non-valvular atrial fibrillation
Conditions
Brief summary
Clinically significant major or non-major bleeding [Period: from randomization to Month 12]. ISTH score (primary), Gusto, TIMI (secondary).
Detailed description
Stroke or systemic embolism [Period: From randomization until Month 12]., Myocardial infarction [Period: From randomization until Month 12]., Death from any cause [Period: From randomization until Month 12]., INR values, interpretation by Rosendaal method, antiXa activity of apixaban at M1, M6, M12, and in case of bleeding.
Interventions
Sponsors
Centre Hospitalier Universitaire De Caen Normandie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinically significant major or non-major bleeding [Period: from randomization to Month 12]. ISTH score (primary), Gusto, TIMI (secondary). | — |
Secondary
| Measure | Time frame |
|---|---|
| Stroke or systemic embolism [Period: From randomization until Month 12]., Myocardial infarction [Period: From randomization until Month 12]., Death from any cause [Period: From randomization until Month 12]., INR values, interpretation by Rosendaal method, antiXa activity of apixaban at M1, M6, M12, and in case of bleeding. | — |
Countries
France
Outcome results
None listed